http://www.immunotechlab.com/ipf/ Current Antiretroviral Therapies Have Serious Limitations: HIV infections are most treatable during its earlier stages but cannot take antiretrovirals during earlier stages, since drug resistance so often develops. Which means limited or no treatment options when viral load and CD4 cell counts are at their worst, i.e., AIDS. Non-antiretroviral treatments like Immunotech IPF remain lacking but are in tremendous demand.
Our therapy is:
• Unique, patent-protected HIV/AIDS therapy • Turns on the immune system to fight HIV infections ? not achieved with other therapies • Inhibits the infection of CD4 T-cells by HIV • Raises CD4 T-cell counts to healthier levels • Reduces HIV viral loads • Replaces or complements current antiretroviral therapies • Potentially lesser costly and much less toxic • May be effective as a periodic therapy instead of a daily one • Likely unaffected by HIV mutations that can hamper antiretroviral therapies (HAART)
Market Data 
Markets 
AI
